89bio, Inc.
ETNB
$9.59
$0.374.01%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.90% | 63.67% | 42.79% | 18.24% | 19.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.47% | 45.50% | 70.30% | 13.61% | -3.35% |
| Operating Income | -62.47% | -45.50% | -70.30% | -13.61% | 3.35% |
| Income Before Tax | -47.92% | -29.56% | -53.24% | -12.80% | 6.99% |
| Income Tax Expenses | 24,068.75% | -- | -- | -- | 110.88% |
| Earnings from Continuing Operations | -63.54% | -29.55% | -53.24% | -12.79% | 6.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.54% | -29.55% | -53.24% | -12.79% | 6.41% |
| EBIT | -62.47% | -45.50% | -70.30% | -13.61% | 3.35% |
| EBITDA | -62.50% | -45.55% | -70.37% | -13.63% | 3.33% |
| EPS Basic | -2.97% | 19.81% | 57.93% | 56.85% | 62.68% |
| Normalized Basic EPS | 4.96% | 19.80% | 57.93% | 55.08% | 60.42% |
| EPS Diluted | -2.97% | 19.81% | 57.93% | 56.85% | 62.68% |
| Normalized Diluted EPS | 4.96% | 19.80% | 57.93% | 55.08% | 60.42% |
| Average Basic Shares Outstanding | 58.82% | 61.55% | 264.23% | 161.42% | 150.77% |
| Average Diluted Shares Outstanding | 58.82% | 61.55% | 264.23% | 161.42% | 150.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
